tcsc6792 Sofiniclin

Sofiniclin (ABT 894) is an agonist of nicotinic acetylcholine receptor (nAChR), used as a potential non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

In Vitro: Sofiniclin is more potent than ABT-089 at both receptor subtypes, with K_i values of 1.9 nM for ¹²⁵I-α-conotoxinMII binding and of 1.3 nM for ¹²⁵I-epibatidine binding^[1].

In Vivo: Sofiniclin (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs compared to vehicle monkey^[1]. Sofiniclin (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage^[2].